Leading Edge Diagnostic and Prognostic Products to Drive Personalized Cancer Treatment

Products being developed and commercialized at CGI are poised to transform cancer patient management, increase treatment efficacy, and reduce healthcare costs. CGI’s cutting-edge proprietary tests and state of the art reference lab provide genomic information where patients and their physicians need it most – to diagnose, monitor and inform cancer treatment.

CGI has developed two categories of next generation, genomic products that are being used in the clinical setting to inform and transform cancer treatment – DNA Fish Probes and Microarrays.

DNA FISH Probes

CGI FISH Probes are currently being used in major cancer centers throughout Europe to confirm diagnosis in Leukemia, Lymphoma and Hematological disorders.

The company is focused on developing an expanding portfolio of DNA FISH probe products in the areas of leukemia, lymphoma, multiple myeloma (MM), myelodysplastic syndrome (MDS), renal cancers, cervical and other HPV associated cancers.

CGI’s DNA-FISH probes are manufactured in Italy by Cancer Genetics Italia S.r.l. and are not commercially available in the US at this time. CGI provides innovative diagnostic reagents of the highest sensitivity and specificity to the clinical community in the European Union and the rest of the world. CGI S.r.l. is located in Milan, Italy. For further information, please go to http://www.cancergeneticsitalia.com.

CGH Microarrays (Chips)

CGI is currently developing and commercializing several CGH-based microarrays based on years of proprietary R&D programs. The cancer microarrays evaluate gene copy number variation (CNV) and gains and losses in DNA in order to provide accurate and timely diagnosis, determine prognosis and guide treatment decisions in selective malignancies including:

• Lymphoma is the 5^th most common type of cancer and accounts for 6% of all cancers in the US.

• Leukemia is the 9^th most common type of cancer in the US.

• Urogential (UG) Cancers account for 43% of cancers in men and 4% of cancers in women.

The Lymphoma Microarray (MatBa™) is currently in trials that are being conducted in collaboration with Long Island Jewish and Memorial Sloan Kettering Hospitals.